Jessica Pollard Loses 70 Pounds on Mounjaro After 1 Year, Easing Sleep Apnea and Joint Pain
Updated
Updated · Newnan Times-Herald · Aug 3
Jessica Pollard Loses 70 Pounds on Mounjaro After 1 Year, Easing Sleep Apnea and Joint Pain
1 articles · Updated · Newnan Times-Herald · Aug 3
Summary
One year after starting Mounjaro in May 2025, 49-year-old Jessica Pollard has lost 70 pounds and entered the maintenance phase, saying the weight loss has eased her sleep apnea and knee pain.
At 217 pounds, Pollard sought treatment after weight gain worsened through perimenopause and dieting failed; she said the GLP-1 drug reduced the "food noise" that had dominated her eating habits.
Dr. Joel Stewart said his practice prescribes GLP-1s mainly for patients with BMI over 30 or lower BMI plus conditions such as diabetes, hypertension, heart disease or sleep apnea, pairing the drugs with nutrition counseling and exercise guidance.
Common side effects include nausea, vomiting, diarrhea and constipation, Stewart said, while longer-term risks can include gastrointestinal problems, pancreatitis, muscle loss and gallbladder disease if rapid weight loss is poorly managed.
CDC data cited in the report show 40.3% of U.S. adults were obese between August 2021 and August 2023, underscoring why GLP-1 drugs such as Mounjaro, Ozempic and Wegovy have become prominent weight-loss treatments.